<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Opioid Analgesics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i85.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i85.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i85.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i56.htm">Analgesics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i83.htm" title="Previous: Tolfenamic Acid">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1206.htm" title="Next: Tapentadol">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i85">Opioid Analgesics</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Opioid Analgesics</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i20.htm">Alcohol</a></td><td>enhanced hypotensive and sedative effects when  opioid analgesics given with alcohol </td><td></td></tr><tr><td><a href="41001i40.htm" name="_40">Anaesthetics, General (intravenous)</a></td><td> opioid analgesics possibly enhance effects of intravenous general anaesthetics </td><td></td></tr><tr><td><a href="41001i46.htm" name="_46">Anaesthetics, General (volatile liquids)</a></td><td> opioid analgesics possibly enhance effects of volatile liquid general anaesthetics </td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td>sedative effects possibly increased when  opioid analgesics given with tricyclics </td><td></td></tr><tr><td><a href="41001i311.htm" name="_311">Antihistamines, Sedating</a></td><td class="cBV"><b>sedative effects possibly increased when  opioid analgesics given with sedating antihistamines </b></td><td></td></tr><tr><td><a href="41001i363.htm" name="_363">Antipsychotics</a></td><td>enhanced hypotensive and sedative effects when  opioid analgesics given with antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i404.htm" name="_404">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  opioid analgesics given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  opioid analgesics inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i553.htm" name="_553">Domperidone</a></td><td> opioid analgesics antagonise effects of domperidone on gastro-intestinal activity</td><td></td></tr><tr><td><a href="41001i257.htm" name="_257">MAOIs</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  opioid analgesics given with MAOIs—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i613.htm" name="_613">Metoclopramide</a></td><td> opioid analgesics antagonise effects of metoclopramide on gastro-intestinal activity</td><td></td></tr><tr><td><a href="41001i262.htm" name="_262">Moclobemide</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  opioid analgesics given with moclobemide—manufacturer of moclobemide advises consider reducing dose of opioid analgesics</b></td><td></td></tr><tr><td><a href="41001i687.htm" name="_687">Selegiline</a></td><td>avoidance of  opioid analgesics advised by manufacturer of selegiline </td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i1067.htm" name="_1067">Sodium Oxybate</a></td><td class="cBV"><b> opioid analgesics enhance effects of sodium oxybate (avoid concomitant use)</b></td><td></td></tr></tbody></table><p>Opioid Analgesics belongs to <b>Analgesics</b>
          but <b>Analgesics</b>
          has no interactions information.
        </p><p><b>Tapentadol</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Alfentanil</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i468.htm">Diltiazem</a></td><td>metabolism of  alfentanil inhibited by diltiazem (risk of prolonged or delayed respiratory depression)</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  alfentanil increased by erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>metabolism of  alfentanil inhibited by fluconazole (risk of prolonged or delayed respiratory depression)</td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>metabolism of  alfentanil possibly inhibited by itraconazole </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  alfentanil accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  alfentanil increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  alfentanil given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  alfentanil increased by voriconazole (consider reducing dose of alfentanil)</b></td><td></td></tr></tbody></table><p><b>Buprenorphine</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>metabolism of  buprenorphine inhibited by ketoconazole (reduce dose of buprenorphine)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  buprenorphine possibly increased by ritonavir </td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td> buprenorphine possibly reduces plasma concentration of tipranavir </td><td></td></tr></tbody></table><p><b>Codeine</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>possible increased risk of antimuscarinic side-effects when  codeine given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  codeine accelerated by rifampicin (reduced effect)</td><td></td></tr></tbody></table><p><b>Dextromethorphan</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i942.htm">Memantine</a></td><td class="cBV"><b>increased risk of CNS toxicity when  dextromethorphan given with memantine (manufacturer of memantine advises avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  dextromethorphan given with moclobemide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>avoid concomitant use of  dextromethorphan with rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr></tbody></table><p><b>Dextropropoxyphene</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> dextropropoxyphene enhances effects of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  dextropropoxyphene increased by ritonavir (risk of toxicity)—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Diamorphine</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Dihydrocodeine</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Diphenoxylate</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Dipipanone</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Fentanyl</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>plasma concentration of  fentanyl possibly increased by triazoles </b></td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td>increased sedative effect when  fentanyl given with baclofen </td><td></td></tr><tr><td><a href="41001i43.htm">Etomidate</a></td><td> fentanyl inhibits metabolism of etomidate (consider reducing dose of etomidate)</td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td> fentanyl possibly inhibits metabolism of midazolam </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  fentanyl accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  fentanyl increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  fentanyl given with saquinavir—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Hydromorphone</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Meptazinol</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Methadone</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>























<tr><td><a href="41001i907.htm">Abacavir</a></td><td>plasma concentration of  methadone possibly reduced by abacavir </td><td></td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with antipsychotics that prolong the QT interval</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  methadone reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i397.htm">Didanosine</a></td><td> methadone possibly reduces plasma concentration of didanosine </td><td>Antacids in tablet formulation may affect absorption of other drugs</td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  methadone reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td>plasma concentration of  methadone possibly increased by fluoxetine </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>plasma concentration of  methadone possibly increased by fluvoxamine </td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>plasma concentration of  methadone reduced by fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>plasma concentration of  methadone reduced by nelfinavir </td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  methadone possibly reduced by nevirapine </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td>plasma concentration of  methadone possibly increased by paroxetine </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  methadone reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>metabolism of  methadone accelerated by phenytoin (reduced effect and risk of withdrawal effects)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  methadone accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  methadone reduced by ritonavir </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  methadone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td>plasma concentration of  methadone possibly increased by sertraline </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  methadone possibly reduced by St John's wort </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>caution with  methadone advised by manufacturer of telaprevir (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  methadone increased by voriconazole (consider reducing dose of methadone)</b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td> methadone possibly increases plasma concentration of zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Morphine</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i617.htm">Baclofen</a></td><td>increased sedative effect when  morphine given with baclofen </td><td></td></tr><tr><td><a href="41001i447.htm">Esmolol</a></td><td> morphine possibly increases plasma concentration of esmolol </td><td></td></tr><tr><td><a href="41001i282.htm">Gabapentin</a></td><td> morphine increases bioavailability of gabapentin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  morphine accelerated by rifampicin (reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  morphine possibly reduced by ritonavir </td><td></td></tr></tbody></table><p><b>Oxycodone</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  oxycodone possibly accelerated by rifampicin </td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td>metabolism of  oxycodone inhibited by telithromycin </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  oxycodone increased by voriconazole </b></td><td></td></tr></tbody></table><p><b>Papaveretum</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Pentazocine</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Pethidine</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  pethidine given with duloxetine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>CNS excitation or depression (hypertension or hypotension) when  pethidine given with MAOIs—avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  pethidine given with moclobemide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>risk of CNS toxicity when  pethidine given with rasagiline (avoid pethidine for 2 weeks after rasagiline)</b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  pethidine reduced by ritonavir , but plasma concentration of toxic pethidine metabolite increased (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>hyperpyrexia and CNS toxicity reported when  pethidine given with selegiline (avoid concomitant use)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr></tbody></table><p><b>Phenazocine</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Remifentanil</b> belongs to
      <b>Opioid Analgesics</b>
          but has no specific interaction information.
        </p><p><b>Tramadol</b> belongs to
      <b>Opioid Analgesics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tramadol given with SSRIs </b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tramadol given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>increased risk of convulsions when  tramadol given with antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td>possible increased risk of convulsions when  tramadol given with atomoxetine </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>effects of  tramadol reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> tramadol enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  tramadol given with duloxetine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>possible increased serotonergic effects and increased risk of convulsions when  tramadol given with MAOIs—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>possible increased serotonergic effects when  tramadol given with mirtazapine </td><td></td></tr><tr><td><a href="41001i1045.htm">Ondansetron</a></td><td>effects of  tramadol possibly antagonised by ondansetron </td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>possible increased serotonergic effects when  tramadol given with venlafaxine </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1206.htm" title="Tapentadol">Tapentadol</a></li><li><a href="41001i86.htm" title="Alfentanil">Alfentanil</a></li><li><a href="41001i87.htm" title="Buprenorphine">Buprenorphine</a></li><li><a href="41001i88.htm" title="Codeine">Codeine</a></li><li><a href="41001i882.htm" title="Dextromethorphan">Dextromethorphan</a></li><li><a href="41001i90.htm" title="Dextropropoxyphene">Dextropropoxyphene</a></li><li><a href="41001i91.htm" title="Diamorphine">Diamorphine</a></li><li><a href="41001i92.htm" title="Dihydrocodeine">Dihydrocodeine</a></li><li><a href="41001i93.htm" title="Diphenoxylate">Diphenoxylate</a></li><li><a href="41001i94.htm" title="Dipipanone">Dipipanone</a></li><li><a href="41001i95.htm" title="Fentanyl">Fentanyl</a></li><li><a href="41001i835.htm" title="Hydromorphone">Hydromorphone</a></li><li><a href="41001i96.htm" title="Meptazinol">Meptazinol</a></li><li><a href="41001i97.htm" title="Methadone">Methadone</a></li><li><a href="41001i98.htm" title="Morphine">Morphine</a></li><li><a href="41001i901.htm" title="Oxycodone">Oxycodone</a></li><li><a href="41001i100.htm" title="Papaveretum">Papaveretum</a></li><li><a href="41001i101.htm" title="Pentazocine">Pentazocine</a></li><li><a href="41001i102.htm" title="Pethidine">Pethidine</a></li><li><a href="41001i103.htm" title="Phenazocine">Phenazocine</a></li><li><a href="41001i105.htm" title="Remifentanil">Remifentanil</a></li><li><a href="41001i106.htm" title="Tramadol">Tramadol</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i83.htm">Previous: Tolfenamic Acid</a> | <a class="top" href="41001i85.htm#">Top</a> | <a accesskey="]" href="41001i1206.htm">Next: Tapentadol</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>